Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Alcohol DrinkingControl
Interventions
DRUG

N-Acetylcysteine

N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.

DRUG

Placebo Oral Capsule

N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Medical University of South Carolina

OTHER

NCT03238300 - Neuroscience-Informed Treatment Development for Adolescent Alcohol Use | Biotech Hunter | Biotech Hunter